Acne Vulgaris in Skin of Color: Understanding Nuances and Optimizing Treatment Outcomes

June 2014 | Volume 13 | Issue 6 | Supplement Individual Articles | 61 | Copyright © June 2014


Andrew F. Alexis MD MPH

Skin of Color Center, Mount Sinai St. Luke’s Roosevelt Hospital, New York, NY
Icahn School of Medicine at Mount Sinai, New York, NY

  1. Identifying and eliminating potentially exacerbating factors that are more prevalent in specific populations (discussed above) is an important step toward ensuring favorable treatment outcomes.

CONCLUSION

The treatment of acne in skin of color patients involves selecting a regimen that ensures early and sustained control of inflammation; avoidance of irritation to prevent iatrogenic dyspigmentation; treatment of both acne lesions and associated PIH; and identification of potential cultural factors that can exacerbate or contribute to acne.

DISCLOSUREs

Andrew F. Alexis MD MPH has served as a consultant for Galderma, Allergan, Estée Lauder, Johnson & Johnson Consumer Companies Inc, L’Oréal, and SkinMedica.

References

  1. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387-394.
  2. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA Jr. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388, 390.
  3. Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512-517.
  4. Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin. 2003;21(4):689-697.
  5. El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol. 2007;56(6):933-938.
  6. Shah SK, Bhanusali DG, Sachdev A, Geria AN, Alexis AF. A survey of skin conditions and concerns in South Asian Americans: a community-based study. J Drugs Dermatol. 2011;10(5):524-528.
  7. Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25(9):1054-1060.
  8. Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):s63-s97.
  9. Alexis AF. Acne in patients with skin of color. J Drugs Dermatol. 2011;10(suppl 6):s13-s16.
  10. Alexis AF, Barbosa VH. Skin of Color: A Practical Guide to Dermatologic Diagnosis and Treatment. New York: Springer; 2013.
  11. Plewig G, Fulton JE, Kligman AM. Pomade acne. Arch Dermatol. 1970;101(5):580-584.
  12. Shah SK, Alexis AF. Acne in skin of color: practical approaches to treatment. J Dermatolog Treat. 2010;21(3):206-211.
  13. Petit A, Cohen-Ludmann C, Clevenbergh P, Bergmann JF, Dubertret L. Skin lightening and its complications among African people living in Paris. J Am Acad Dermatol. 2006;55(5):873-878.
  14. Halder RM, Holmes YC, Bridgeman-Shah S, Kligman AM. A clinical pathological study of acne vulgaris in black females. J Invest Dermatol. 1996;106:888.
  15. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20-27.
  16. Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol. 1993;100(suppl 2):s191-s195.
  17. Thiboutot DM. Inflammasome activation by Propionibacterium acnes: the story of IL-1 in acne continues to unfold. J Invest Dermatol. 2014;134(3):595-597.
  18. Kistowska M, Gehrke S, Jankovic D, et al. IL-1β drives inflammatory responses to Propionibacterium acnes in vitro and in vivo. J Invest Dermatol. 2014;134(3):677-685.
  19. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500-506.
  20. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142(5):597-602.
  21. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006;142(5):605-612.
  22. Fleischer AB Jr, Simpson JK, McMichael A, Feldman SR. Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States? J Am Acad Dermatol. 2003;49(4):662-666.
  23. Pariser D, Colón LE, Johnson LA, Gottschalk RW. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drugs Dermatol. 2008;7(suppl 6):s18-s23.
  24. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy potential of adapalene cream 0.1% compared with adapalene gel 0.1% and several tretinoin formulations. Cutis. 2003;72(6):455-458.
  25. Tu P, Li GQ, Zhu XJ, Zheng J, Wong WZ. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol. 2001;15 (suppl 3):s31-s36.
  26. Goh CL, Tang MB, Briantais P, Kaoukhov A, Soto P. Adapalene gel 0.1% is better tolerated than tretinoin gel 0.025% among healthy volunteers of various ethnic origins. J Dermatolog Treat. 2009;20(5):282-288.
  27. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):s37-s42.
  28. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(suppl 4):48-54.
  29. Kubota Y, Munehiro A, Shirahige Y, et al. Effect of sequential application of topical adapalene and clindamycin phosphate in the treatment of Japanese patients with acne vulgaris. J Dermatolog Treat. 2012;23(1):37-45.
  30. Tirado-Sánchez A1, Espíndola YS, Ponce-Olivera RM, Bonifaz A. Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV). J Cosmet Dermatol. 2013;12(2):103-107.
  31. Alexis AF, Johnson LA, Kerrouche N, Callender VD. A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne. J Drugs Dermatol. 2014;13(2):170-174.
  32. Callender VD, Preston N, Osborn C, Johnson L, Gottschalk RW. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol. 2010;3(8):15-19.
  33. Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11(5):643-648.
  34. Callender VD, Young CM, Kindred C, Taylor SC. Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color. J Clin Aesthet Dermatol. 2012;5(7):25-32.
  35. Taylor SC. Utilizing combination therapy for ethnic skin. Cutis. 2007;80(suppl 1):s15-s20.
  36. Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):s98-s106.
  37. Zeichner J. Strategies to minimize irritation and potential iatrogenic post-inflammatory pigmentation when treating acne patients with skin of color. J Drugs Dermatol. 2011;10(suppl 12):s25-s26.
  38. Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24-38.
  39. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438-1443.
  40. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45-50.

AUTHOR CORRESPONDENCE

Andrew F. Alexis MD MPHalexisderm@yahoo.com
Close Menu